Bibliographic record
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR…. BMJ 2019
§1Bibliographic record
§1.1Record
- Authors
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A
- Title
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- Source
- BMJ
- Year
- 2019
- Volume, issue, pages
- 366:l4898
- Digital object identifier
- 10.1136/bmj.l4898
- PubMed identifier
- 31462531
- Record type
- Journal article
- Institute identifier
- CEI-BR-104
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Larazotide acetate | Compound monograph |
| Monograph: Semax | Compound monograph |
| Monograph: Selank | Compound monograph |
| Monograph: Epithalon | Compound monograph |
| Monograph: SS-31 (elamipretide) | Compound monograph |
| Synthesis: Larazotide acetate in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: Semax in cognitive performance and neuroprotection: effect on the… | Evidence synthesis |
| Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and… | Evidence synthesis |
| Synthesis: Larazotide acetate in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: Semax in cognitive performance and neuroprotection: tolerability and… | Evidence synthesis |
| Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and… | Evidence synthesis |
| 11 citing documents. | |
§1.3Subject tags
risk-of-bias methodology
Compound Evidence Institute · CEI-BR-104 · https://compoundevidence.com/bibliography/sterne2019/ · retrieved 30 July 2026